Lecia Sequist, MD, MPH - Episode 2

EGFR Mutations and Targeted Therapy in NSCLC

EP. 1: EGFR TKIs for Upfront Treatment of NSCLC
Now Viewing
EP. 2: EGFR Mutations and Targeted Therapy in NSCLC
EP. 3: Mechanisms of Resistance to Upfront EGFR-Targeted Therapy
EP. 4: Sequencing of Therapies in EGFR-Mutant NSCLC

Related Content:

Lecia Sequist, MD, MPHLung Cancer
The OncFive: Top Oncology Articles for the Week of 11/10
Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC